Trial · NCT05862233
A Phase Ⅲ Clinical Study of MIL62 in Primary Membranous Nephropathy
NCT05862233, Phase 3, Unknown, Beijing Mabworks Biotech Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Phase Ⅲ Clinical Study of MIL62 in Primary Membranous Nephropathy. Trials, record NCT05862233. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05862233
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Phase Ⅲ Clinical Study of MIL62 in Primary Membranous Nephropathy
- NCT number
- NCT05862233
- Status
- Unknown
- Phases
- Phase 3
- Enrollment
- 150 participants, estimated
- Lead sponsor
- Beijing Mabworks Biotech Co., Ltd.
- Conditions
- Primary Membranous Nephropathy
- Interventions
- MIL62, Cyclosporine
- First posted
- 2023-05-17
- Last updated
- 2025-08-20
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Complete remission rate at Week 76 | Week 76 | The proportion of participants who achieved complete remission (CR) based on Urine Protein-to-Creatinine Ratio (UPCR) at week 76. |
| Secondary | Complete Remission rate at Week 52. | Week 52 | The proportion of participants who achieved CR based on UPCR at week52 (key secondary endpoints) |
| Secondary | Overall remission rate at Week 52 and 76. | Week 52 and 76 | The proportion of participants who achieved overall remission(OR) based on UPCR at week 52 and week76. |
| Secondary | Complete remission rate and Overall remission rate at Week 24 and 104. | Week 24 and 104 | The proportion of participants who achieved CR and OR based on UPCR at week 24 and week 104. |
| Secondary | Complete remission rate and Overall remission rate at Week 24，52，76 and 104. | Week 24，52，76 and 104 | The proportion of participants who achieved CR or OR as assessed by the Investigators based on 24-hour urine protein at week 24, week 52, week 76 and week 104. |
| Secondary | Time to Treatment Failure or Relapse after Overall remission | Up to 104 weeks | Time to Treatment Failure or Relapse after Complete or Partial Remission |
| Secondary | Change in efficacy indicators | Baseline to Week 104 | Change in anti-PLA2R Autoantibody Titer, UPCR, eGFR, 24-hour urine protein and ALB |
| Secondary | Change in quality of life | Baseline to Week 104 | Mean Change in T-score from Baseline in the EQ5D Scale at Week 104 |
| Secondary | Percentage of Participants with Adverse Events (AEs) | up to 104 weeks | Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0 |
| Secondary | Percentage of Participants with AEs of Special Interest (AESIs) | Up to 104 weeks |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05862233
GET https://conductscience.org/api/trials/v1/NCT05862233/registered